Abstract: The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids. The compositions of the invention may also comprise probiotic bacteria. The compositions of the invention include compositions for preventing or delaying the onset of hepatocellular cancer by treating or preventing liver inflammation, liver disease, and precancerous lesions.

Abstract: Apparatus for increasing burning efficiency including a bottom shell having a plate defining a first opening for receiving a fuel source and a side wall extending in an upward direction. The side wall has a first side wall end coupled to the plate and a second side wall end spaced from the first side wall end in the upward direction. Additionally, the apparatus includes a top shell having inner and outer walls defining a cavity for receiving the second side wall end of the side wall of the bottom shell. The inner wall has a first inner end and a second inner end and the outer wall has a first outer end and a second outer end. The first inner end is coupled to the first outer end and the second inner end is spaced from the second outer end to receive at least the second side wall end.

Abstract: Provided herein are luminescent compounds, compositions including the same, and use and synthesis thereof.

Abstract: The present invention relates to compositions and methods for masking the taste of an agent. In certain aspects, the invention comprises a microsphere and at least one sweetener therein. In another aspect, the invention comprises an edible material comprising at least one microsphere comprising an agent and at least one microsphere comprising a sweetener.

Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

Abstract: Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gaucher's disease, and any disease or condition involving lysosomal storage dysfunction.

Abstract: The invention provides methods of treating ischemia/reperfusion injury in a subject. In one example, a method comprises administering a therapeutically effective amount of a pharmaceutical composition that increases levels of Bcl2-associated athanogene 3 (BAG3) polypeptide in ischemic tissue. The invention also provides methods of treating a subject at risk of ischemia/reperfusion injury. In one example, a method comprises administering a therapeutically effective amount of a pharmaceutical composition that increases levels of Bcl2-associated athanogene 3 (BAG3) polypeptide. In the invention methods, in one example, a pharmaceutical composition comprises a nucleic acid encoding BAG3 polypeptide.

Abstract: Aspects of the invention are directed to systems and apparatuses for efficiently burning fuels. According to one aspect of the invention, apparatus for efficiently burning hydrocarbons includes a housing having a first opening for receiving a fuel, a second opening for expelling the fuel, and a tubular passageway extending between the first opening and the second opening. The tubular passageway includes a central region and an outer region surrounding the central region. The apparatus also includes a plurality of magnets disposed within the passageway. Each of the magnets has a spherical or an ovoid shape. The plurality of magnets define void spaces for passing the fuel such that a central flow rate of the fuel in the central region of the passageway is equivalent to the an outer flow rate of the fuel in an outer region of the passageway.

Abstract: The present invention includes novel aminothiazole compounds of formula (I), which are useful in preventing or treating cancer in a subject in need thereof.

Abstract: The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.

Abstract: The invention includes compositions and methods useful for the diagnosis and treatment of head or brain injury in a subject in need thereof, based upon the expression level of at least one miRNA that is associated with head or brain injury.

Abstract: The invention provides one or more of miR-290 family and Lin28a modified cardiac progenitor cell based therapies for the treatment of myocardial infarction. Exosomes derived from one or more of miR-290 family and Lin28a modified cardiac progenitor cells can also be used in cardiac therapy.

Abstract: The present invention relates to a new pneumatic-actuated multifunctional doming actuator. The doming actuator can be used as a doming actuator, which can maintain machine/robotic operation on vertical surfaces without falling. The doming actuators exhibit rapid switchable adhesion/deadhesion on target surfaces upon pressurizing/depressurizing the embedded spiral pneumatic channels. The present invention also relates to novel load-carrying and climbing soft robots using the doming actuators. The soft robots are operable on a wide range of horizontal and vertical surfaces including dry, wet, slippery, smooth, and semi-smooth surfaces. In addition, the doming actuators can be used as a driving actuator for swimming soft robotics and as an actuator for soft grippers.

Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.

Abstract: The present invention provides porous biomimetic scaffolds and methods for making the same. The scaffolds have graded pore sizes for enhanced cell penetration. The scaffolds are useful for wound regeneration by facilitating cell penetration into the scaffold interior and due to their inherent immunomodulatory effects. The scaffolds have tissue modeling specification by mimicking the inherent stratified structure of certain tissues.

Abstract: Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.

Abstract: The present invention provides in part wearable devices for balance control. The wearable devices are capable of non-invasively monitoring and stimulating the wearer's vestibular system such that it produces postural responses. The wearable devices deliver low levels of electrical current to the vestibular system of a user to maintain balance. In one example, the wearable device is in the form of a pair of glasses.

Abstract: A magnetometer-based metal detection device and methods of use are described. The device includes a proximal portion, a central body and a distal portion, and at least one magnetometer positioned within or on the distal portion. The at least one magnetometer includes at least one sensor capable of sensing a magnetic field in three orthogonal axes. Also described is a method of calibrating the device to achieve rotational invariance, and a method of determining a directionality or directional line along which a target metal object lies.

Abstract: Systems and methods for reducing blood viscosity along a flow direction, suppressing turbulence in blood flow, and treating rouleaux are disclosed. One method includes applying a unidirectional magnetic field to a flow of blood in a direction parallel or antiparallel to a direction of the flow of blood, and maintaining the application of the unidirectional magnetic field to the flow of blood until a blood viscosity along the direction of the flow of blood is reduced and/or the turbulence in the blood flow is suppressed. One system includes an annular magnet sized to encircle a portion of a patient's body. The magnet is adapted to generate a unidirectional magnetic field in a region within the annular magnet. The unidirectional magnetic field has a strength sufficient to reduce the blood viscosity in the portion of the patient's body and/or suppress turbulence in the blood flow by a predetermined amount. The system will also break rouleaux for patients with rouleaux, but the process will take more time.

Abstract: The invention provides a novel ceramic-metal oxide-polymer composite material. A functionalized metal oxide nanolayer coating can be bonded between LICGCs and polymers/oligomers, which protects the LICGC from corrosion, has a low interfacial resistance to Li+ migration, and can be a SIC. Hybrid ceramic-polymer electrolytes were formed by engineering the interface between a LICGC and a polymer, polyethylene oxide (PEO), by sputter coating a 200 nm thick SiO2 layer onto a lithium ion conducting glass ceramic (LICGC) and silanating the SiO2 with a functionalized PEG in the presence of LiTFSI. A low interfacial resistance (Rinterfacial) was measured, the same as that obtained for a SiO2 interface soaked with liquid tetraglyme/LiTFSI. The pegylated SiO2 interface (unlike the tetraglyme/LiTFSI interface) protected the LICGC from corrosion by Li0 metal. The (PEG-LiTFSI)—SiO2-LICGC could be bonded with polyethylene oxide/LiTFSI.